FTSE 100 news / Companies and sectors / GSK / FDA approves GSK's Jemperli for rectal cancer
FDA approves GSK's Jemperli for rectal cancer
+9.7 strongly positive
FDA approved Jemperli for MSI-H/dMMR locally advanced rectal cancer.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| MedCity News | 1 | +10.0 |
| Dealroom | 1 | +10.0 |
| BioWorld News | 1 | +10.0 |
| MedWatch | 1 | +10.0 |
| James Sharp & Co. | 1 | +10.0 |
| GSK US | 1 | +10.0 |
| Fierce Pharma | 1 | +10.0 |
| FirstWord Pharma | 1 | +10.0 |
| StreetInsider | 1 | +10.0 |
| GenomeWeb | 1 | +9.7 |
| Pharmaceutical Executive | 1 | +9.7 |
| MarketScreener | 1 | +9.5 |
| Benzinga | 1 | +9.5 |
| Investing.com | 1 | +9.5 |
| Pink Sheet | 1 | +9.2 |
| Quiver Quantitative | 1 | +8.3 |
| Stock Titan | 1 | +8.3 |
| Seeking Alpha | 1 | +7.5 |
| GuruFocus | 1 | +6.7 |
Day by day
Wednesday 21 October 2026
The FDA granted accelerated approval to Jemperli for MSI-H/dMMR rectal cancer.
- +10.0 GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
Accelerated FDA approval for Jemperli in rectal cancer - +10.0 GSK's Jemperli wins FDA accelerated approval as first immunotherapy for MSI-H/dMMR locally advanced rectal cancer
First immunotherapy approved for locally advanced rectal cancer - +10.0 GSK’s Jemperli wins accelerated nod in rectal cancer
Jemperli accelerated approval in rectal cancer - +10.0 GSK wins FDA approval for rectal cancer drug
FDA approval for rectal cancer drug - +10.0 GSK's Jemperli Approved in MSI-H/dMMR Rectal Cancer October 20, 2026
Jemperli approved in MSI-H/dMMR rectal cancer
Tuesday 20 October 2026
FDA approved Jemperli for MSI-H/dMMR locally advanced rectal cancer.
- +10.0 Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
First and only immunotherapy approved for this rectal cancer. - +10.0 GSK’s Jemperli scores FDA approval in rectal cancer, backed by high complete response rate
Approval backed by high complete response rate. - +10.0 GSK's Jemperli gets US nod for biomarker-defined rectal cancer
US approval for biomarker-defined rectal cancer. - +10.0 FDA approves GSK's Jemperli for a specific rectal cancer type
FDA approves Jemperli for rectal cancer type. - +9.7 FDA Approves GSK’s Jemperli for First-Line MSI-High, dMMR Rectal Cancer
FDA approves Jemperli first-line for rectal cancer. - +9.7 FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer
Accelerated approval for Jemperli in rectal cancer. - +9.5 GSK's Jemperli Receives FDA Approval to Treat Some Patients With Advanced Rectal Cancer
Jemperli approved for some advanced rectal cancer patients. - +9.5 FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
FDA clears drug that could change rectal cancer treatment. - +9.5 GSK’s Jemperli wins FDA approval for rectal cancer treatment
Jemperli wins FDA approval for rectal cancer. - +9.2 GSK’s Jemperli Rectal Cancer Indication Becomes US FDA’s 11th National Priority Voucher Approval
Jemperli approval via FDA priority voucher. - +8.3 AnaptysBio Announces FDA Approval of GSK’s Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer Based on AZUR-1 Data
Partner announces FDA approval of GSK's Jemperli. - +8.3 A newly approved rectal cancer drug could help eligible patients avoid chemo, radiation and surgery
New drug could spare patients chemo, radiation, surgery. - +7.5 AnaptysBio gains as GSK granted FDA label expansion for Jemperli
Label expansion granted for Jemperli. - +6.7 AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo
Partner's shares rise after GSK label expansion.